High-grade (Gleason ≥8) prostate cancers with low PSA (<4) are uniquely resistant to testosterone suppression, but this meta-analysis of 145 such cases treated across four randomized trials indicates a reduction in prostate cancer-specific (HR 0.42) and overall (HR 0.51) survival with the addition of docetaxel. | Mahal, JAMA Netw Open 2023
